Pharma Innovation: Europe Is Being Edged Into Third Place

With a declining share of global R&D and investment, Europe risks the pharmaceutical industry being increasingly molded in the image of others.  

Third place
• Source: Shutterstock

Each year, the European Federation of Pharmaceutical Industries and Associations (EFPIA) publishes an annual factbook to emphasize the tremendous strategic importance of the pharmaceutical industry to the continent. Among the key figures, European companies collectively invest approximately €40bn in R&D annually, rising at a compound annual growth rate (CAGR) of 4.0% since 2017. An impressive figure at face value, although one that the US eclipses with more than €70bn spent, with an equivalent growth rate of 8.5%.

While the trans-Atlantic equilibrium continues to tilt away from Europe and to the US, a new powerhouse in China is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.